Biohaven Total Liab vs Cash Analysis

BHVN Stock

USD 39.32 1.95 5.22%

Biohaven Pharmaceutical financial indicator trend analysis is way more than just evaluating Biohaven Pharmaceutical prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Biohaven Pharmaceutical is a good investment. Please check the relationship between Biohaven Pharmaceutical Total Liab and its Cash accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biohaven Pharmaceutical Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

Total Liab vs Cash

Total Liab vs Cash Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Biohaven Pharmaceutical Total Liab account and Cash. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Biohaven Pharmaceutical's Total Liab and Cash is 0.84. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Cash in the same time period over historical financial statements of Biohaven Pharmaceutical Holding, assuming nothing else is changed. The correlation between historical values of Biohaven Pharmaceutical's Total Liab and Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Biohaven Pharmaceutical Holding are associated (or correlated) with its Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash has no effect on the direction of Total Liab i.e., Biohaven Pharmaceutical's Total Liab and Cash go up and down completely randomly.

Correlation Coefficient

0.84

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Cash

Cash refers to the most liquid asset of Biohaven Pharmaceutical, which is listed under current asset account on Biohaven Pharmaceutical Holding balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Biohaven Pharmaceutical customers. The amounts must be unrestricted with restricted cash listed in a different Biohaven Pharmaceutical account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.

Most indicators from Biohaven Pharmaceutical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Biohaven Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biohaven Pharmaceutical Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

At this time, Biohaven Pharmaceutical's Selling General Administrative is very stable compared to the past year. As of the 20th of May 2024, Enterprise Value is likely to grow to about 3.2 B, though Tax Provision is likely to grow to (1.3 M).

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	1.4M	1.4M	6.9M	7.3M
Cost Of Revenue	91.7M	1.4M	3.4M	3.2M

Reconciled Depreciation Cost Of Revenue

Biohaven Pharmaceutical fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Short Long Term Debt Total	Common Stock Shares Outstanding	Other Liab	Net Tangible Assets	Current Deferred Revenue	Other Assets	Net Receivables	Short Term Investments
Total Assets		0.82	0.87	0.81	0.84	-0.38	0.16	0.83	0.66	0.83	-0.4	0.98	0.34	0.69	-0.11	0.53	1.0	0.18	-0.36	0.44	0.61	0.69	-0.88	0.04	-0.58	-0.18
Other Current Liab	0.82		0.99	0.52	0.79	0.03	-0.32	0.62	0.42	0.81	-0.65	0.75	0.42	0.47	0.36	0.63	0.79	0.58	0.12	-0.03	0.63	0.35	-0.7	0.36	-0.64	-0.08
Total Current Liabilities	0.87	0.99		0.55	0.81	-0.05	-0.27	0.73	0.53	0.83	-0.61	0.82	0.47	0.55	0.32	0.67	0.85	0.56	0.06	0.09	0.66	0.41	-0.74	0.27	-0.66	-0.16
Total Stockholder Equity	0.81	0.52	0.55		0.86	-0.37	0.39	0.52	0.26	0.75	-0.39	0.75	-0.15	0.8	-0.32	0.02	0.79	-0.03	-0.6	0.51	0.64	0.82	-0.95	-0.15	-0.64	-0.31
Property Plant And Equipment Net	0.84	0.79	0.81	0.86		-0.07	-0.1	0.63	0.28	0.92	-0.71	0.75	0.05	0.85	0.17	0.26	0.8	0.47	-0.22	0.34	0.86	0.66	-0.97	-0.01	-0.86	-0.49
Net Debt	-0.38	0.03	-0.05	-0.37	-0.07		-0.84	-0.47	-0.62	0.13	-0.42	-0.51	-0.37	-0.38	0.76	-0.32	-0.45	0.67	0.85	-0.65	0.26	-0.72	0.27	0.66	-0.29	-0.05
Retained Earnings	0.16	-0.32	-0.27	0.39	-0.1	-0.84		0.07	0.23	-0.24	0.52	0.25	-0.11	0.14	-0.97	-0.17	0.22	-0.92	-0.9	0.52	-0.37	0.57	-0.15	-0.48	0.39	0.24
Accounts Payable	0.83	0.62	0.73	0.52	0.63	-0.47	0.07		0.9	0.6	-0.14	0.89	0.67	0.72	0.03	0.76	0.84	0.23	-0.25	0.62	0.52	0.56	-0.64	-0.24	-0.47	-0.43
Cash	0.66	0.42	0.53	0.26	0.28	-0.62	0.23	0.9		0.27	0.21	0.78	0.82	0.41	-0.16	0.84	0.71	-0.03	-0.29	0.52	0.11	0.43	-0.33	-0.25	-0.06	-0.12
Non Current Assets Total	0.83	0.81	0.83	0.75	0.92	0.13	-0.24	0.6	0.27		-0.74	0.72	0.0	0.66	0.26	0.24	0.78	0.54	0.0	0.27	0.9	0.43	-0.87	0.26	-0.87	-0.41
Non Currrent Assets Other	-0.4	-0.65	-0.61	-0.39	-0.71	-0.42	0.52	-0.14	0.21	-0.74		-0.25	0.22	-0.41	-0.48	0.01	-0.33	-0.7	-0.22	0.08	-0.69	-0.24	0.59	-0.2	0.68	0.36
Cash And Short Term Investments	0.98	0.75	0.82	0.75	0.75	-0.51	0.25	0.89	0.78	0.72	-0.25		0.47	0.68	-0.18	0.63	0.99	0.09	-0.43	0.5	0.5	0.72	-0.81	-0.07	-0.47	-0.16
Non Current Liabilities Total	0.34	0.42	0.47	-0.15	0.05	-0.37	-0.11	0.67	0.82	0.0	0.22	0.47		0.15	0.21	0.97	0.39	0.2	0.1	0.09	-0.07	0.08	0.0	-0.11	0.07	0.02
Other Current Assets	0.69	0.47	0.55	0.8	0.85	-0.38	0.14	0.72	0.41	0.66	-0.41	0.68	0.15		-0.01	0.26	0.67	0.23	-0.44	0.7	0.74	0.78	-0.87	-0.47	-0.73	-0.74
Other Stockholder Equity	-0.11	0.36	0.32	-0.32	0.17	0.76	-0.97	0.03	-0.16	0.26	-0.48	-0.18	0.21	-0.01		0.27	-0.17	0.94	0.87	-0.46	0.44	-0.5	0.08	0.41	-0.48	-0.33
Total Liab	0.53	0.63	0.67	0.02	0.26	-0.32	-0.17	0.76	0.84	0.24	0.01	0.63	0.97	0.26	0.27		0.56	0.32	0.11	0.1	0.12	0.17	-0.2	0.0	-0.12	-0.01
Total Current Assets	1.0	0.79	0.85	0.79	0.8	-0.45	0.22	0.84	0.71	0.78	-0.33	0.99	0.39	0.67	-0.17	0.56		0.12	-0.41	0.45	0.55	0.71	-0.85	0.0	-0.52	-0.14
Common Stock	0.18	0.58	0.56	-0.03	0.47	0.67	-0.92	0.23	-0.03	0.54	-0.7	0.09	0.2	0.23	0.94	0.32	0.12		0.7	-0.3	0.64	-0.22	-0.23	0.35	-0.66	-0.43
Short Long Term Debt Total	-0.36	0.12	0.06	-0.6	-0.22	0.85	-0.9	-0.25	-0.29	0.0	-0.22	-0.43	0.1	-0.44	0.87	0.11	-0.41	0.7		-0.63	0.15	-0.84	0.43	0.65	-0.17	-0.01
Common Stock Shares Outstanding	0.44	-0.03	0.09	0.51	0.34	-0.65	0.52	0.62	0.52	0.27	0.08	0.5	0.09	0.7	-0.46	0.1	0.45	-0.3	-0.63		0.32	0.65	-0.48	-0.67	-0.23	-0.61
Other Liab	0.61	0.63	0.66	0.64	0.86	0.26	-0.37	0.52	0.11	0.9	-0.69	0.5	-0.07	0.74	0.44	0.12	0.55	0.64	0.15	0.32		0.29	-0.77	0.15	-0.99	-0.69
Net Tangible Assets	0.69	0.35	0.41	0.82	0.66	-0.72	0.57	0.56	0.43	0.43	-0.24	0.72	0.08	0.78	-0.5	0.17	0.71	-0.22	-0.84	0.65	0.29		-0.8	-0.59	-0.27	-0.28
Current Deferred Revenue	-0.88	-0.7	-0.74	-0.95	-0.97	0.27	-0.15	-0.64	-0.33	-0.87	0.59	-0.81	0.0	-0.87	0.08	-0.2	-0.85	-0.23	0.43	-0.48	-0.77	-0.8		0.12	0.76	0.43
Other Assets	0.04	0.36	0.27	-0.15	-0.01	0.66	-0.48	-0.24	-0.25	0.26	-0.2	-0.07	-0.11	-0.47	0.41	0.0	0.0	0.35	0.65	-0.67	0.15	-0.59	0.12		-0.19	0.47
Net Receivables	-0.58	-0.64	-0.66	-0.64	-0.86	-0.29	0.39	-0.47	-0.06	-0.87	0.68	-0.47	0.07	-0.73	-0.48	-0.12	-0.52	-0.66	-0.17	-0.23	-0.99	-0.27	0.76	-0.19		0.66
Short Term Investments	-0.18	-0.08	-0.16	-0.31	-0.49	-0.05	0.24	-0.43	-0.12	-0.41	0.36	-0.16	0.02	-0.74	-0.33	-0.01	-0.14	-0.43	-0.01	-0.61	-0.69	-0.28	0.43	0.47	0.66

Click cells to compare fundamentals

Biohaven Pharmaceutical Account Relationship Matchups

Biohaven Pharmaceutical fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	344.3M	111.5M	142.1M	661.8M	513.2M	347.2M
Other Current Liab	52.1M	27.1M	37.2M	79.3M	36.5M	38.6M
Total Current Liabilities	66.2M	29.9M	41.9M	90.0M	55.4M	49.1M
Total Stockholder Equity	(7.4M)	16.8M	34.7M	538.8M	428.0M	449.4M
Property Plant And Equipment Net	8.2M	13.6M	18.2M	52.4M	48.6M	51.0M
Net Debt	(316.7M)	185.0M	550.7M	(174.3M)	(218.8M)	(207.9M)
Retained Earnings	(972.4M)	(1.7B)	(2.6B)	(91.1M)	(499.3M)	(524.3M)
Accounts Payable	14.1M	2.8M	4.8M	10.7M	15.6M	10.0M
Cash	316.7M	82.5M	76.1M	204.9M	249.7M	151.5M
Non Current Assets Total	16.0M	21.7M	47.2M	74.8M	70.8M	40.6M
Non Currrent Assets Other	7.8M	1.0M	3.2M	2.6M	2.4M	4.2M
Cash And Short Term Investments	316.7M	82.5M	76.1M	465.3M	383.1M	270.2M
Liabilities And Stockholders Equity	344.3M	111.5M	142.1M	661.8M	513.2M	347.2M
Non Current Liabilities Total	285.5M	4.8M	5.4M	33.0M	29.8M	55.3M
Other Current Assets	11.6M	10K	2.1M	19.3M	45.7M	47.9M
Other Stockholder Equity	83.5M	98.9M	169.7M	13.9M	39.8M	73.8M
Total Liab	351.7M	34.7M	47.4M	123.0M	85.2M	91.0M
Total Current Assets	328.3M	89.8M	94.8M	587.0M	442.4M	306.6M
Common Stock	881.4M	1.2B	1.7B	615.7M	887.5M	970.6M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Biohaven Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biohaven Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biohaven Pharmaceutical Holding Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biohaven Pharmaceutical Holding Stock:

How To Invest In Biohaven

Details

Is Biohaven Stock a good investment?

Details

What is Biohaven Pharmaceutical's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biohaven Pharmaceutical Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Complementary Tools for Biohaven Stock analysis

When running Biohaven Pharmaceutical's price analysis, check to measure Biohaven Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biohaven Pharmaceutical is operating at the current time. Most of Biohaven Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Biohaven Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biohaven Pharmaceutical's price. Additionally, you may evaluate how the addition of Biohaven Pharmaceutical to your portfolios can decrease your overall portfolio volatility.

	Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments
	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon
	Stocks Directory Find actively traded stocks across global markets
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments

Is Biohaven Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biohaven Pharmaceutical. If investors know Biohaven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biohaven Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(6.90)

Return On Assets

(0.65)

Return On Equity

(1.34)

The market value of Biohaven Pharmaceutical is measured differently than its book value, which is the value of Biohaven that is recorded on the company's balance sheet. Investors also form their own opinion of Biohaven Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biohaven Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biohaven Pharmaceutical's market value can be influenced by many factors that don't directly affect Biohaven Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Biohaven Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biohaven Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biohaven Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Biohaven Total Liab vs Cash Analysis

Total Liab vs Cash

Total Liab vs Cash Correlation Analysis

Correlation Coefficient

Total Liab

Cash

Biohaven Pharmaceutical fundamental ratios Correlations

Biohaven Pharmaceutical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Biohaven Pharmaceutical fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Biohaven Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Total Current Liabilities	+ 0.99	Other Current Liab
Total Current Assets	+ 0.99	Cash And Short Term Investments
Cash And Short Term Investments	+ 0.98	Total Assets
Total Liab	+ 0.97	Non Current Liabilities Total
Common Stock	+ 0.94	Other Stockholder Equity

Net Receivables	- 0.99	Other Liab
Other Stockholder Equity	- 0.97	Retained Earnings
Current Deferred Revenue	- 0.97	Property Plant And Equipment Net
Current Deferred Revenue	- 0.95	Total Stockholder Equity
Common Stock	- 0.92	Retained Earnings
Short Long Term Debt Total	- 0.9	Retained Earnings